Zydus, China Medical System enter licensing agreement for desidustat Medical Dialogues Bureau21 Jan 2020 9:45 AM GMTUnder the license agreement, CMS will pay Zydus an initial upfront payment, regulatory milestones, sales milestones and royalties on net sales of the...
Zydus Cadila unveils affordable anti-diabetic drug Vildagliptin under brands Vinglyn, Vinglyn M Medical Dialogues Bureau12 Dec 2019 6:23 AM GMTAhmedabad: With the Novartis Blockbuster Vildagliptin going off patent, Zydus Cadila has taken made its move towards affordable diabetes care in India...
Zydus Cadila receives warning letter from USFDA for Moraiya-based formulation facility Medical Dialogues Bureau5 Nov 2019 7:27 AM GMTNew Delhi: Drug firm Zydus Cadila on Monday said it has received a warning letter from the US health regulator for its Moraiya-based formulation...
Cadila Healthcare largest API manufacturing site clears USFDA inspection Medical Dialogues Bureau12 Oct 2019 6:11 AM GMTThe US Food and Drug Administration (USFDA) inspected the company's active pharmaceutical ingredients (API) manufacturing facility at Dabhasa from...
Zydus Cadila gets USFDA nod for Colesevelam Hydrochloride tablets for lowering cholesterol Medical Dialogues Bureau10 Oct 2019 6:04 AM GMTZydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Colesevelam Hydrochloride tablets,...
CDSCO warns against Cancer Causing Impurities in anti-acidity drug Ranitidine, writes to state drug controllers Farhat Nasim25 Sep 2019 7:49 AM GMTNew Delhi: To ensure patient safety, the country's apex drug regulatory body, Central Drugs Standard Control Organisation (CDSCO) has ordered an...
Zydus Cadila wins DCGI nod for marketing rabies drug Twinrab Medical Dialogues Bureau3 Sep 2019 4:30 AM GMT"The novel biologic which will be marketed under the brand name, Twinrab, is indicated in combination with rabies vaccine for rabies post-exposure...
Zydus Cadila total income up by 21 percent to Rs 3496 crore in Q1 Medical Dialogues Bureau10 Aug 2019 7:13 AM GMTDuring the quarter, Zydus Cadila entered into a marketing alliance with SIFI, the Italian leader in the development of therapeutic solutions for...
Zydus Cadila completes phase III trial of Diabetes drug Lipaglyn in India Medical Dialogues Bureau5 Aug 2019 4:30 AM GMTSaroglitazar Magnesium was launched in India during September 2013, under the brand name 'Lipaglyn', for the treatment of hypertriglyceridemia and...
Zydus Cadila wins USFDA nod for Minocycline Hydrochloride ER tablets to treat acne Medical Dialogues Bureau3 Aug 2019 4:15 AM GMTMinocycline hydrochloride extended-release tablets are indicated to treat only inflammatory lesions of non-modular moderate to severe acne vulgaris in...
Novartis Expiry of Patent for Blockbuster Vildagliptin to Clear Way for Competitors Farhat Nasim30 July 2019 8:38 AM GMTNew Delhi: The patent protection of blockbuster anti-diabetic drug Vildagliptin manufactured by the Swiss drugmaker, Novartis, will soon expire on...
Zydus Cadila launches Ramelteon tablets in US to treat insomnia Medical Dialogues Bureau25 July 2019 5:53 AM GMTIn a BSE filing, Zydus Cadila announced the "launch of Ramelteon tablets, 8 mg upon receiving the final approval from the USFDA. Ramelteon is a...